| Crockett Medical Clinic Inc | |
|
58 S. Bells St Alamo TN 38001 | |
| (731) 696-5401 | |
| (731) 696-5404 |
| Full Name | Crockett Medical Clinic Inc |
|---|---|
| Speciality | Clinic/Center |
| Location | 58 S. Bells St, Alamo, Tennessee |
| Authorized Official Name and Position | Charles Richard Jerman (CFO) |
| Authorized Official Contact | 7316964670 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Crockett Medical Clinic Inc 58 S. Bells St Alamo TN 38001 Ph: (731) 696-5401 | Crockett Medical Clinic Inc 58 S. Bells St Alamo TN 38001 Ph: (731) 696-5401 |
| NPI Number | 1104839703 |
|---|---|
| Provider Enumeration Date | 08/14/2006 |
| Last Update Date | 07/02/2019 |
| Medicare PECOS PAC ID | 8921009812 |
|---|---|
| Medicare Enrollment ID | O20070119000217 |
News Archive
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem's live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem's strategy, and this research is part of the work towards that goal.
New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.
An international team of scientists, involving Professor Rodrigo Quian Quiroga, director of the Centre for Systems Neuroscience and Head of Bioengineering at the University of Leicester, has shown how individual neurons in the human brain react to ambiguous morphed faces.
Novasep, a leading supplier of manufacturing solutions to the life sciences industry, today announces that it is expanding its presence in South East Asia with the opening of an office in Bangkok, Thailand.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104839703 | NPI | - | NPPES |
| 3717707 | Medicaid | TN | |
| 3717707 | Other | TN | PTAN |
| Provider Name | Raymond W Rhear |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1659384253 PECOS PAC ID: 9436146370 Enrollment ID: I20040430000554 |
News Archive
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem's live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem's strategy, and this research is part of the work towards that goal.
New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.
An international team of scientists, involving Professor Rodrigo Quian Quiroga, director of the Centre for Systems Neuroscience and Head of Bioengineering at the University of Leicester, has shown how individual neurons in the human brain react to ambiguous morphed faces.
Novasep, a leading supplier of manufacturing solutions to the life sciences industry, today announces that it is expanding its presence in South East Asia with the opening of an office in Bangkok, Thailand.
› Verified 1 days ago
| Provider Name | Karen E Webb |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1902819501 PECOS PAC ID: 7517955446 Enrollment ID: I20040430001308 |
News Archive
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem's live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem's strategy, and this research is part of the work towards that goal.
New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.
An international team of scientists, involving Professor Rodrigo Quian Quiroga, director of the Centre for Systems Neuroscience and Head of Bioengineering at the University of Leicester, has shown how individual neurons in the human brain react to ambiguous morphed faces.
Novasep, a leading supplier of manufacturing solutions to the life sciences industry, today announces that it is expanding its presence in South East Asia with the opening of an office in Bangkok, Thailand.
› Verified 1 days ago
| Provider Name | Lori F Laman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295906378 PECOS PAC ID: 5597844001 Enrollment ID: I20080509000046 |
News Archive
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem's live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem's strategy, and this research is part of the work towards that goal.
New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.
An international team of scientists, involving Professor Rodrigo Quian Quiroga, director of the Centre for Systems Neuroscience and Head of Bioengineering at the University of Leicester, has shown how individual neurons in the human brain react to ambiguous morphed faces.
Novasep, a leading supplier of manufacturing solutions to the life sciences industry, today announces that it is expanding its presence in South East Asia with the opening of an office in Bangkok, Thailand.
› Verified 1 days ago
| Provider Name | Donna P Clement |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1629272620 PECOS PAC ID: 8628145596 Enrollment ID: I20080917000833 |
News Archive
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem's live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem's strategy, and this research is part of the work towards that goal.
New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.
An international team of scientists, involving Professor Rodrigo Quian Quiroga, director of the Centre for Systems Neuroscience and Head of Bioengineering at the University of Leicester, has shown how individual neurons in the human brain react to ambiguous morphed faces.
Novasep, a leading supplier of manufacturing solutions to the life sciences industry, today announces that it is expanding its presence in South East Asia with the opening of an office in Bangkok, Thailand.
› Verified 1 days ago
| Provider Name | Kristin Byrd |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1548569700 PECOS PAC ID: 2163609009 Enrollment ID: I20110602000260 |
News Archive
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem's live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem's strategy, and this research is part of the work towards that goal.
New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.
An international team of scientists, involving Professor Rodrigo Quian Quiroga, director of the Centre for Systems Neuroscience and Head of Bioengineering at the University of Leicester, has shown how individual neurons in the human brain react to ambiguous morphed faces.
Novasep, a leading supplier of manufacturing solutions to the life sciences industry, today announces that it is expanding its presence in South East Asia with the opening of an office in Bangkok, Thailand.
› Verified 1 days ago
| Provider Name | Loren S Carroll |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1104168178 PECOS PAC ID: 0749409209 Enrollment ID: I20150421001883 |
News Archive
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem's live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem's strategy, and this research is part of the work towards that goal.
New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.
An international team of scientists, involving Professor Rodrigo Quian Quiroga, director of the Centre for Systems Neuroscience and Head of Bioengineering at the University of Leicester, has shown how individual neurons in the human brain react to ambiguous morphed faces.
Novasep, a leading supplier of manufacturing solutions to the life sciences industry, today announces that it is expanding its presence in South East Asia with the opening of an office in Bangkok, Thailand.
› Verified 1 days ago
| Provider Name | Samantha French |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1528698271 PECOS PAC ID: 2365870581 Enrollment ID: I20220209000240 |
News Archive
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem's live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem's strategy, and this research is part of the work towards that goal.
New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.
An international team of scientists, involving Professor Rodrigo Quian Quiroga, director of the Centre for Systems Neuroscience and Head of Bioengineering at the University of Leicester, has shown how individual neurons in the human brain react to ambiguous morphed faces.
Novasep, a leading supplier of manufacturing solutions to the life sciences industry, today announces that it is expanding its presence in South East Asia with the opening of an office in Bangkok, Thailand.
› Verified 1 days ago
| Provider Name | Meredith Paige Gaitley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1811634835 PECOS PAC ID: 5890171771 Enrollment ID: I20220929001961 |
News Archive
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem's live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem's strategy, and this research is part of the work towards that goal.
New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.
An international team of scientists, involving Professor Rodrigo Quian Quiroga, director of the Centre for Systems Neuroscience and Head of Bioengineering at the University of Leicester, has shown how individual neurons in the human brain react to ambiguous morphed faces.
Novasep, a leading supplier of manufacturing solutions to the life sciences industry, today announces that it is expanding its presence in South East Asia with the opening of an office in Bangkok, Thailand.
› Verified 1 days ago
News Archive
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem's live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem's strategy, and this research is part of the work towards that goal.
New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.
An international team of scientists, involving Professor Rodrigo Quian Quiroga, director of the Centre for Systems Neuroscience and Head of Bioengineering at the University of Leicester, has shown how individual neurons in the human brain react to ambiguous morphed faces.
Novasep, a leading supplier of manufacturing solutions to the life sciences industry, today announces that it is expanding its presence in South East Asia with the opening of an office in Bangkok, Thailand.
› Verified 1 days ago
Alamo Family Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 157 N Bells St, Alamo, TN 38001 Phone: 731-696-5551 Fax: 731-696-2802 |